News

A study found that progression-free survival, but not overall survival, was worse among obese patients with EC treated with pembrolizumab.

A study showed the high-risk of endometrial cancer (HIREC) score can improve the prediction of high-risk cancers preoperatively.

Vaginal brachytherapy is beneficial in some women with endometrial cancer who developed vaginal recurrence.

A scoping review maps exercise programs studied after endometrial cancer treatment and highlights early benefits and research gaps.

Although EC is strongly linked with obesity, other factors including metabolic instability should also be considered, a recent study found.

MRI-guided brachytherapy achieved high pelvic tumor control with minimal serious side effects in vaginal recurrence of endometrial cancer.

Younger women with endometrial cancer generally experience good outcomes, especially with early-stage, low-grade tumors.

A patient first presented with EC symptoms a year before diagnosis but was not immediately treated, causing aggressive cancer progression.

Some forms of hormone replacement therapy may increase the risk of endometrial hyperplasia among postmenopausal women.

OncoMate MSI Dx test received FDA approval as a companion diagnostic to determine MSI status and support treatment in endometrial cancer.